MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients

Journal of Clinical Pharmacology

Volumn 43, Issue 10, 2003, Pages 1101-1107

  Mai, Ingrid ^a,b   Störmer, Elke ^a   Goldammer, Mark ^a   Johne, Andreas ^a   Krüger, Hagen ^a   Budde, Klemens ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cyclosporine; Haplotype; MDR1; P glycoprotein; Patients; Pharmacokinetics

Indexed keywords

ACARBOSE; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CYCLOSPORIN A; CYTOCHROME P450 3A; CYTOSINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOPROTEIN P; GUANINE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; POTASSIUM; PYRROLE DERIVATIVE; SANDIMMUN OPTORAL; SULFONYLUREA DERIVATIVE; THYMINE; UNINDEXED DRUG; VITAMIN D;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG FORMULATION; EXON; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERICUM PERFORATUM; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; MICROEMULSION; MULTIDRUG RESISTANCE; PARAMETER; PHARMACOKINETICS; POLYMERASE CHAIN REACTION; RANK SUM TEST; RECIPIENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE;

ADULT; AGED; AREA UNDER CURVE; CYCLOSPORINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, MDR; GERMANY; HAPLOTYPES; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0141765814     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003257222     Document Type: Article

References (38)

1. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-698.
2. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, et al: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988;48:1926-1929.
3. Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR: Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 1983;67:869-874.
4. Fromm MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002;54:1295-1310.
5. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478.
6. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-534.
7. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, et al: MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002;54:610-616.
8. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-199.
9. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72:209-219.
10. Gaston RS: Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001;38:S25-S35.
11. Hebert MF: Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997;27:201-214.
12. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-260.
13. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 1996;118:1841-1847.
14. Christians U, Strohmeyer S, Kownatzki R, Schiebel HM, Bleck J, Kohlhaw K, et al: Investigations on the metabolic pathways of cyclosporine: II. Elucidation of the metabolic pathways in vitro by human liver microsomes. Xenobiotica 1991;21:1199-1210.
15. Christians U, Sewing KF: Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993;57:291-345.
16. Fahr A: Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24:472-495.
17. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, et al: Metabolism of cyclosporin A: IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
18. Campana C, Regazzi MB, Buggia I, Molinaro M: Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet 1996;30:141-179.
19. Capone D, Aiello C, Santoro GA, Gentile A, Stanziale P, D'Alessandro R, et al: Drug interaction between cyclosporine and two antimicrobial agents, josamycin and rifampicin, in organ-transplanted patients. Int J Clin Pharmacol Res 1996;16:73-76.
20. Bauer S, Störmer E, Johne A, Krüger H, Budde K, Neumayer HH, et al: Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203-211.
21. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001;47:1048-1052.
22. Min DI, Ellingrod VL: C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002;24:400-404.
23. Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002;72:584-594.
24. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al: Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000;97:10483-10488.
25. Hoehe MR, Köpke K, Wendel B, Rohde K, Flachmeier C, Kidd KK. et al: Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 2000;9:2895-2908.
26. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-174.
27. Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB: Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 1990;265:506-514.
28. Terwillinger J, Ott J: Handbook of Human Genetic Linkage. Baltimore: Johns Hopkins University Press, 1994.
29. International Neoral Renal Transplantation Study Group: Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002;2:157-166.
30. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, et al: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 2002;63:765-770.
31. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74:1486-1489.
32. Loor F, Tiberghien F, Wenandy T, Didier A, Traber R: Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. J Med Chem 2002;45:4598-4612.
33. Wood AJJ, Stein CM: "Inactive" ingredients may alter bioavailability of drugs through effects on P-glycoprotein (PGP) and CYP3A. Clin Pharmacol Ther 2001;69:P71.
34. Tayrouz Y, Ding R, Borwitzky H, Haefeli WE, Mikus G: Oral cremophor RH 40 affects only digoxin absorption. Eur J Clin Pharmacol 2001;57:A21.
35. Wang EJ, Casciano CN, Clement RP, Johnson WW: In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 2000;28:522-528.
36. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002;2:191-196.
37. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, et al: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 2002;74:571-572.
38. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359:30-36.